GlassScriptPhysician profile
Mukesh Shah
NPI 1801867395
$7,040.18
in general payments reported to CMS, 2019-2025
47 companies · $702 in 2025
The $702 reported for 2025 was more than what 79% of Internal Medicine providers received nationally (typical 2025 total: $156).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,118 · 2020: $1,045 · 2021: $1,193 · 2022: $903 · 2023: $924 · 2024: $1,156 · 2025: $702.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,782.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,781.61 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals LP | $1,490.90 | 2019-2025 | Farxiga, Breztri, Tezspire |
| Lilly USA, LLC | $702.69 | 2019-2025 | Emgality, Jardiance, Mounjaro |
| Novo Nordisk INC | $515.65 | 2019-2025 | Ozempic, Rybelsus, Wegovy |
| Pfizer INC. | $389.69 | 2019-2024 | |
| Boston Scientific Corporation | $335.72 | 2019-2022 | |
| Glaxosmithkline, LLC. | $303.95 | 2021-2025 | Trelegy Ellipta, Shingrix, Arexvy |
| Amarin Pharma, INC. | $288.79 | 2019-2022 | |
| Becton, Dickinson and Company | $238.44 | 2024 | Phasix Mesh |
| Novartis Pharmaceuticals Corporation | $213.46 | 2019-2024 | |
| Merck Sharp & Dohme LLC | $210.91 | 2019-2023 | Belsomra |
| Amgen INC. | $189.60 | 2022-2024 | Otezla, Repatha |
| Xeris Pharmaceuticals, INC. | $181.29 | 2022-2025 | Gvoke Hypopen |
| Abbvie INC. | $150.29 | 2020-2025 | |
| Exact Sciences Corporation | $149.11 | 2023-2025 | Cologuard Collection Kit |
| Allergan, INC. | $124.57 | 2019-2020 |
Show all 47 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Mukesh Shah listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.